University of Pennsylvania HIV Clinical Trials Unit

摘要 宾夕法尼亚大学HIV临床试验单位（Penn HIV CTU）将在现有基础设施的基础上 并进一步承诺提供科学领导，以推进艾滋病毒治疗科学， 艾滋病毒临床研究网络（Adult AIDS Clinical Trials Group，ACTG） 疫苗试验组（HVTN）和艾滋病毒预防试验组（HPTN）。宾州艾滋病毒CTU的特点是， 一个整合的、高效的临床试验组织，拥有两个临床研究中心（CRS），Penn Therapeutics CRS，位于宾夕法尼亚大学医学院（PSOM）校园，进行ACTG试验;和宾夕法尼亚大学 预防CRS，单独位于宾夕法尼亚大学校园，进行HVTN和HPTN支持的试验。 宾夕法尼亚大学的研究人员将继续通过参与这些网络的科学议程作出贡献。 通过提交协议和加入协议小组，在网络委员会中发挥作用。此外，本发明还提供了一种方法， 宾夕法尼亚大学艾滋病毒CTU将通过成本效益， 开展临床试验，改善艾滋病毒感染者的生活， 那些处于危险之中的人。宾夕法尼亚大学艾滋病毒CTU的领导层将通过以下方式指导下一代临床研究人员： 让我们研究中心和其他地方的初级研究者参与促进其职业发展的活动， 网络和站点级别。宾夕法尼亚大学的调查人员将在以下情况下与受艾滋病毒影响的当地社区接触： 制定优先事项，我们将告知社会参与研究的机会，并教育 社区了解医学进步和获得它们的机会。宾夕法尼亚大学的调查人员 通过评估旨在控制艾滋病毒感染的策略， 在没有抗逆转录病毒药物的情况下清除HIV复制的潜伏库，测试抑制新药物 艾滋病毒复制，并通过改善治疗和预防与艾滋病毒有关的并发症 感染宾夕法尼亚大学的研究人员还通过艾滋病毒检测为艾滋病毒预防的进步做出了贡献 用于暴露前预防的疫苗、长效抗逆转录病毒药物和单克隆抗体， 旨在改变危险行为的行为干预。我们的目标是让这些进步 所有感染艾滋病毒或有感染艾滋病毒风险的人口，包括男男性行为者、顺性别妇女， 变性人和性别不一致者以及注射毒品者。鉴于资源， 愿景和承诺，宾夕法尼亚大学的研究人员，宾夕法尼亚大学艾滋病毒CTU是很好的定位，以支持倡议， 通过在艾滋病毒预防、诊断、 治疗

ABSTRACT The University of Pennsylvania HIV Clinical Trials Unit (Penn HIV CTU) will build on its current infrastructure and further its commitment to provide scientific leadership to advance the science of HIV treatment and prevention within three HIV Clinical Research Networks, the Adult AIDS Clinical Trials Group (ACTG), the HIV Vaccine Trials Group (HVTN), and the HIV Prevention Trials Group (HPTN). The Penn HIV CTU features an integrated, efficient clinical trials organization with two clinical research sites (CRS), the Penn Therapeutics CRS, located on the Penn School of Medicine (PSOM) campus, that conducts ACTG trials; and the Penn Prevention CRS, separately located on the Penn campus, that conducts HVTN and HPTN supported trials. Penn investigators will continue to contribute to the scientific agendas of these Networks through participation on network committees and through submission of protocols and membership on protocol teams. In addition, the Penn HIV CTU will advance the research agendas of these Networks through the cost efficient implementation of clinical trials to improve the lives of people living with HIV infection and to prevent it among those at risk. The leadership of the Penn HIV CTU will mentor the next generation of clinical investigators by involving junior investigators at our site and elsewhere in activities at that promote their career development at both the Network and site level. Penn investigators will engage the local community affected by HIV when formulating priorities, we will inform the community about opportunities to participate in research, and educate the community about medical advances and opportunities to access them. Penn investigators have contributed to important advances in HIV therapeutics through the evaluation of strategies designed to control HIV replication in the absence of antiretrovirals and purge the latent reservoir, testing of novel agents to inhibit HIV replication, and by improving treatments and prevention of co-morbid conditions associated with HIV infection. Penn investigators have also contributed to advances in HIV prevention through the testing of HIV vaccines, long-acting antiretrovirals and monoclonal antibodies for pre-exposure prophylaxis, and through behavioral interventions designed to modify risk behaviors. It is our goal to make these advances available to all populations living with or at-risk for HIV infection, including men who have sex with men, cisgender women, transgender and gender non-conforming individuals, and persons who inject drugs. Given the resources, vision, and commitment of Penn investigators, the Penn HIV CTU is well positioned to support the initiative for Ending the HIV Epidemic in Philadelphia, a priority city, through achievements in HIV prevention, diagnosis, treatment.